Published in Physician Law Weekly, March 23rd, 2005
Because of the sale of Ciphergen's BioSepra chromatography business to Pall Corp. on November 30, 2004, the financial results discussed herein reflect the BioSepra business as a discontinued operation.
For the quarter ended December 31, 2004, total revenue decreased 13% to $10.1 million, as compared to $11.6 million in the fourth quarter of 2003; but total revenue increased 19% sequentially as compared to the third quarter of 2004. The net loss from continuing operations was $7.6 million in the fourth quarter of 2004 as...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly